Telbivudine

Telbivudine

File:Telbivudine structure.svg
Systematic (IUPAC) name
1-(2-deoxy-β-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione
Clinical data
Trade names	Tyzeka
AHFS/Drugs.com	monograph
MedlinePlus	a607045
Licence data	EMA:Link, US FDA:link
Pregnancy category	US: B (No risk in non-human studies)
Legal status	UK: POM (Prescription only) US: ℞-only
Routes of administration	Oral
Pharmacokinetic data
Protein binding	Low (3.3% in vitro)
Metabolism	Nil
Biological half-life	40 to 49 hours (terminal phase)
Excretion	Renal
Identifiers
CAS Number	3424-98-4 Y
ATC code	J05AF11 (WHO)
PubChem	CID: 159269
DrugBank	DB01265 Y
ChemSpider	140081 Y
UNII	2OC4HKD3SF Y
ChEMBL	CHEMBL374731 N
Synonyms	1-(2-deoxy-β-L-ribofuranosyl)-5-methyluracil β-L-2-deoxythymidine β-L-thymidine (LdT) 1-[(2S,4R,5S)-4-hydroxy-5-hydroxymethyltetrahydrofuran-2-yl]-5-methyl-1H-pyrimidine-2,4-dione
Chemical data
Formula	C10H14N2O5
Molecular mass	242.23 g/mol
SMILES O=C/1NC(=O)N(\C=C\1C)[C@H]2O[C@H]([C@H](O)C2)CO
InChI InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1 Y Key:IQFYYKKMVGJFEH-CSMHCCOUSA-N Y
NY (what is this?)  (verify)

Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance.

Telbivudine is a synthetic thymidine nucleoside analogue; it is the L-isomer of thymidine. It is taken orally in a dose of 600 mg once daily with or without food.

External links

• Tyzeka official website run by Novartis Pharmaceuticals Corporation
• Telbivudine entry in RxList
• Sebivo Summary of Product Characteristics (from the EMEA website)